文献速递胸部肿瘤

T-DXd在HER2突变NSCLC跨治疗线的系统与颅内疗效及安全性:TRACER/HERTras真实世界队列

Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Mutant NSCLC Across Treatment Lines: Evidence From the TRACER/HERTras Real-World Cohort.
PubMed 文献 · J Thorac Oncol · 2026-02-24

这项回顾性多国队列研究纳入2021年8月至2025年1月欧洲和以色列68个中心168例接受T-DXd治疗的晚期HER2突变NSCLC患者。总体ORR为54.8%,中位PFS 7.2个月,中位OS 18.3个月;初治患者ORR 72.2%,可测量脑转移患者颅内ORR 74.1%。≥3级治疗相关不良事件发生率32%,间质性肺病/肺炎发生率14%(4例致死)。

要点

  • T-DXd在真实世界HER2突变NSCLC中显示稳健的系统疗效,总体ORR 54.8%,DCR 88.7%。
  • 初治患者ORR达72.2%,可测量脑转移患者颅内ORR 74.1%,支持前线及颅内应用。
  • 间质性肺病/肺炎发生率14%,含4例致死,为主要安全性关注点。

核心结论

  • T-DXd在HER2突变晚期NSCLC真实世界队列中显示稳健的系统与颅内活性,包括初治和活动性脑转移患者。
  • 毒性特征与既往报告一致,间质性肺病仍是主要安全性关注点。
  • 结果支持将HER2靶向治疗整合入不断演变的治疗算法。

研究设计与样本

  • 回顾性、多国队列研究,纳入2021年8月至2025年1月欧洲和以色列68个中心接受T-DXd临床试验外治疗的晚期HER2突变NSCLC患者。
  • 共纳入168例患者,中位年龄62岁,女性59%,从不吸烟者56%。
  • 主要终点为客观缓解率(ORR),次要终点包括无进展生存期(PFS)、总生存期(OS)、颅内疗效和安全性。

主要发现

  • 总体ORR为54.8%(95%CI 46.9-62.4),疾病控制率为88.7%(95%CI 82.9-93.1)。
  • 中位PFS为7.2个月(95%CI 6.2-9.7),中位OS为18.3个月(95%CI 13.3-24.8)。
  • 初治患者(n=18)ORR为72.2%(95%CI 46.5-90.3),中位OS为22.1个月(95%CI 10.0-不可评估)。
  • 可测量脑转移患者(n=27)颅内ORR为74.1%(95%CI 53.7-88.9),其中完全缓解占25.9%。
  • ≥3级治疗相关不良事件发生率为32%,间质性肺病/肺炎发生率为14%(4例致死),无一致预测因素。

临床怎么用

  • T-DXd可作为HER2突变晚期NSCLC的系统治疗选择,包括初治患者和活动性脑转移患者。
  • 治疗期间需重点监测间质性肺病/肺炎,因发生率14%且含致死病例。

局限性

  • 回顾性研究设计,存在选择偏倚和信息偏倚可能。
  • 初治患者(n=18)和可测量脑转移患者(n=27)样本量较小,相关亚组结果需谨慎解读。
  • 间质性肺病无一致预测因素,安全性风险识别受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: HER2 mutations define a distinct, therapeutically actionable subset of NSCLC. Trastuzumab deruxtecan (T-DXd) has demonstrated strong activity in clinical trials, but real-world data are limited. METHODS: We conducted a retrospective, multinational cohort study of patients with advanced HER2-mutant NSCLC treated with T-DXd outside clinical trials between August 2021 and January 2025 across 68 centers in Europe and Israel. The primary end point was objective response rate (ORR). Secondary end points included progression-free survival (PFS), overall survival (OS), intracranial efficacy, and safety. RESULTS: Among 168 patients (median age 62 y; 59% female; 56% never-smokers), the ORR was 54.8% (95% confidence interval [CI]: 46.9-62.4) and disease control rate was 88.7% (95% CI: 82.9-93.1). Median PFS was 7.2 months (95% CI: 6.2-9.7) and median OS was 18.3 months (95% CI: 13.3-24.8). Treatment-naive patients (n = 18) achieved an ORR of 72.2% (95% CI: 46.5-90.3) and a median OS of 22.1 months (95% CI: 10.0-not evaluable). Patients with measurable brain metastases (n = 27) had an intracranial ORR of 74.1% (95% CI: 53.7-88.9), including 25.9% complete responses. Grade 3 or higher treatment-related adverse events occurred in 32% of patients. Interstitial lung disease/pneumonitis occurred in 14% (four fatal cases) of patients, without consistent predictors. CONCLUSIONS: In the largest real-world cohort reported to date, T-DXd demonstrated robust systemic and intracranial activity in HER2-mutant NSCLC, including treatment-naive patients and those with active brain metastases who were largely excluded from prior studies. Toxicity was consistent with previous reports, with interstitial lung disease remaining the main safety concern. These findings support integration of HER2-targeted therapies into evolving treatment algorithms.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Illini O, Hund AC, Kopp HG, et al. Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Mutant NSCLC Across Treatment Lines: Evidence From the TRACER/HERTras Real-World Cohort. J Thorac Oncol. 2026. PMID: 41747890. doi:10.1016/j.jtho.2026.103651

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。